Synendos Therapeutics AG is a biopharmaceutical company dedicated to developing novel therapeutics for the treatment of a wide range of central nervous system (CNS) disorders based on modulation of the endocannabinoid pathway. 

Synendos is a spinout from the University of Bern in Switzerland and is based on several years of academic research in the role of the endocannabinoid system (ECS) in inflammation and neuromodulation. The ECS is involved in regulation of fear, stress and anxiety, and changes in the system have been associated with several severe neuropsychiatric and neuroinflammatory disorders.

For more information, please contact:

Søren Lemonius, MSc

Managing General Partner


  